

EXECUTIVE DIRECTORS



Jakob Sigurdsson Chief Executive Officer



Richard Armitage Chief Financial Officer



Martin Court
Chief Commercial
Officer





ENVIRONMENT

ACHIEVE NET ZERO CARBON EMISSIONS

Minimise use of resources (energy, waste, water) used in our own operations

2021: 28,454 tonnes

2030: Net Zero (Scope 1

& 2 emissions)



SUSTAINABLE SOLUTIONS THAT **ADDRESS WORLD MATERIAL CHALLENGES EVERY DAY**

WE BRING TRANSFORMATIONAL &

SUSTAINABLE SOLUTIONS

BRING ENVIRONMENTAL & SOCIETAL BENEFITS







Develop and deliver sustainable polymer solutions that provide environmental and societal benefits evidenced by data

> 2021: 50% revenue 2030: 70% revenue

SOCIAL

HAVE A POSITIVE IMPACT ON THE **COMMUNITIES WHERE WE WORK**



STEM INSPIRATION

Science, Technology, Engineering & Maths

Inspire the next generation: increase annual contacts reached

> 2021: 1,600 Goal: 2,500



COMMUNITY ACTVITIY

Maintain strong community engagement (cumulative hours target)

2021: 3,500 2030: 10,000



FEMALES IN LEADERSHIP (top two grades)

Enhance inclusion & diversity

2021: 10% 2030: 40%

SAFETY, HEALTH & WELLBEING

Achieve a Zero accident & Zero incident culture

Recordable Frequency Injury Rate

Current: 0.7

Goal: Zero

GOVERNANCE

ESG Centre of Excellence

- Increase disclosures and reporting
- Signed up to SBTi Targets
- New Board Corporate Responsibility Committee



SCIENCE BASED

TARGETS



















H1 2022 HIGHLIGHTS



GOOD PROGRESS WITH ESG

- 100% renewable electricity across all UK sites
- Victrex joins Apple Clean Energy Supplier programme
- New Corporate Responsibility Committee established

¹ Alternative performance measures are defined in the Appendix on slide 29 *Available cash of £41.9m excludes £3.8m of cash ring-fenced in the Group's Chinese subsidiaries and includes £0.1m in 95-day notice deposit accounts

STRONG FIRST HALF, VOLUMES +8%

- Double-digit growth in Electronics, Energy & Industrial, VAR
- Recent improvement in Automotive, despite Semiconductor chip challenges
- Medical revenue +12% as elective surgeries return
- 6% increase in new application growth pipeline

UNDERLYING PBT UP 3% & 10% IN CONSTANT CURRENCY

- Underlying profit before tax (PBT) up 3% at £48.2m
- Reported PBT down 6% reflecting £4.6m exceptional items (expensed ERP software implementation)
- Gross margin broadly stable (improvement impacted by inflation & FX)

GOOD PROGRESS IN MEGA-PROGRAMME GROWTH PIPELINE

- Strong progress in PEEK Knee clinical trial, 15 implants & recruitment at halfway stage
- New business wins for next generation E-mobility programme
- Good progress in Magma; supporting scale-up in Brazil

STRONG CASH GENERATION

- H1 2022 available cash¹ of £41.9m*, H1 dividend of 13.42p/share
- Good progress on new PEEK facility in China; commissioning in 2022

SUMMARY: STRONG CORE GROWTH & CONTINUING ACTION TO MITIGATE INFLATION

- Operational improvements offset inflation in H1
- Additional price recovery well advanced for H2

P&L

STRONG CORE GROWTH

- H1 2022 volumes +8% at 2,264 tonnes
- Revenue +6%
- Underlying PBT +3% at £48.2m

Half year (6 months) ended 31 March


Revenue	H1 2022 £m 160.1	H1 2021 £m 150.9	Change % 6 %	Change (constant currency) ¹ %
Gains on foreign currency net hedging*	1.7	0.5	238%	
Gross profit	85.0	81.4	4 %	8%
Gross margin % Overheads**	<i>53.1%</i> (36.4)	53.9% (34.4)	-80bps -6%	
Exceptionals	(4.6)	-		
Finance income less share of associate	(0.4)	(0.4)	-	
Profit before tax and exceptionals	48.2	46.6	3%	
Profit before tax	43.6	46.6	-6%	-1%
Adjusted earnings per share ¹	47.8p	46.9p	2%	
Earnings per share	43.5p	46.9p	-7%	
Dividend per share	13.42p	13.42p		

^{*} Gains or Losses on foreign currency contracts, when net hedging is applied on cash flow hedges, are disclosed separately within gross margin.


^{**}Excluding exceptional items of £4.6m (H1 2021: £nil)

UNDERLYING PBT BRIDGE

H1 2021 v H1 2022



ASP & MARGIN



SEQUENTIAL ASP IMPROVEMENT AT £71/kg (H2 2021: £68/kg)

- H1 2022 ASP up 4% sequentially
- ASP reflects continued strong growth in Industrial; improvement in Medical

GM IMPROVEMENT OFFSET BY COST INFLATION

• H1 2022 GM 53.1% (improvement towards mid-term target, excluding cost inflation & FX)

MARGIN BRIDGE & MARGIN RECOVERY

DRIVERS OF MARGIN RECOVERY

Operational efficiency & asset utilisation; sales mix; China commercialisation

Investment in green energy/alternative fuels & processes





CURRENCY

Sizeable FY22 headwind...

	H1 2022				H1 2021		Change
	Reported	Exc deals	Currency Spot Impact	Constant currency ¹	As reported	Exc Deals	Constant currency ¹
	£m	£m	£m	£m	£m	£m	£m
Revenue	160.1	160.1	3.8	163.8	150.9	150.9	9%
Gain on foreign currency net hedging	1.7	-	-	-	0.5	-	
Gross profit	85.0	83.4	4.0	87.4	81.4	80.9	8%
Gross margin %	53.1%	52.1%	-	53.4%	53.9%	53.6%	
Profit before tax	43.6	41.9	3.9	45.9	46.6	46.1	0%
Exchange rates	H1 2021 ²	H2 2021 ²	FY 2021 ²	H1 2022 ²	H2 2022 ²	FY 2022 ²	Exchange rate sensitivity ³
\$/£	1.31	1.29	1.28	1.37	1.38	1.32	£4.9m
€/£	1.14	1.14	1.14	1.14	1.17	1.19	£5.8m

¹ Alternative performance measures are defined in the Appendix on slide 29

9

² Effective rates (includes the impact of hedging)

³ Management estimate of impact on 2022 full year forecast PBT from a 5% movement in weighted average spot exchange rates (before the impact of hedging)



CASH

Solid cash generation...

	H1 2022 H1 2021	
	£m	£m
Operating profit before tax & exceptionals	48.6	47.0
Depreciation & amortisation	10.9	10.5
EBITDA	59.5	57.5
Change in working capital	(21.9)	4.2
Capital expenditure	(26.7)	(16.5)
Operating cash flow	10.9	45.2
Operating cash conversion	22.4%	96.2%
Interest	0.1	(0.0)
Tax	(5.6)	(0.9)
Exceptional costs	(4.6)	-
Other	4.2	(2.6)
Free cash flow	5.0	41.7
Acquisitions	(1.4)	(2.0)
Disposals	4.5	-
Borrowings	9.3	5.9
Dividends	(83.5)	(40.0)
Other	36.5	2.0
Cash flow	(29.6)	7.6
Exchange differences	0.4	(1.1)
Cash at 1st October	74.9	73.1
Cash at 31st March	45.7	79.6

UNDERPIN GROWTH & RETURNS

- Strong cash generation supports investment for growth
- Good mid-term dividend return opportunities
- H1 dividend 13.42p/share



INDUSTRIAL UPDATE



AUTOMOTIVE: RECENT IMPROVEMENT SUPPORTS GROWTH FOCUS

- H1 2022 Automotive down 8% (sequential improvement + 13% Q2 vs Q1);
 impacted by Semicon
- New business wins in E-mobility; further progress in PEEK Gears



AEROSPACE: STEADY IMPROVEMENT; LONG TERM OPPORTUNITIES

- H1 2022 Aerospace +4%
- Long term programmes remain robust: Loaded Brackets & Aero Structures
- Further industry collaborations for composite programmes



Mature Annualised Revenue (MAR¹) £303m (H1 2021: £285m)



ENERGY & INDUSTRIAL: CONTINUED STRONG GROWTH

- H1 2022 Energy & Industrial +14% (Energy +23%)
- Good progress in Food, Robotics, General Manufacturing



ELECTRONICS: FURTHER PROGRESS

H1 2022 Electronics +8%; growth in Semicon and mobile applications

VALUE ADDED RESELLERS (VAR)

H1 2022 volumes +14% despite strong comparators; further opportunity in H2

E-MOBILITY (19)



New business wins

COMMERCIAL PROGRESS WITH VICTREX XPI™ POLYMER

- Broad portfolio of development programmes (Asia, Europe, US)
- New business wins across insulation & coating applications
- PEEK processability offers strong ESG credentials (vs enamel)













HYBRID FLEXIBLE PIPE -A FREE HANGING RISER **SOLUTION** Rigid Flexible **HFP**

SUPPORT QUALIFICATION AHEAD OF TECHNIP FMC CAPEX / SCALE-UP IN BRAZIL (2022/2023)

MEDICAL UPDATE

H1 2022 REVENUE +12% TO £27.8m

- Growth in all regions
- Spine +1%, offset by Omicron impact
- Strong progress on Knee & Trauma

GOOD PROGRESS IN NON-SPINE; +25%

- Growth across all segments: Trauma, Dental, Cardio, Ortho
- H2 2022 launches for Trauma & In2Bones partnership
- Good growth in Cardio



PEEK KNEE

Halfway through clinical trial recruitment

STRONG PROGRESS TO DATE

- 15 patients implanted
- 3 patients post-12 month stage
- US clinical trial targeted in H2 2022
- Closing in on additional partner (top 5 orthopaedic company)



MEGA-PROGRAMMES


Strong growth pipeline...

Probability of success (indicative)

KEY CHANGES:

E-mobility: Revenue progression

Revenue progression




TODAY

Gears:

Size of bubble

= potential annual revenue in peak year (all bubbles are indicative only)





Position and colour of bubble = time to meaningful revenue:






VICTREX PATH TO NET ZERO


Our Net Zero ambition is centred on reducing climate impacts from our own operations

A Bold 2030 Vision

Our net zero goal by 2030 was set in 2020 and is significant and ambitious. It intentionally focuses and invests to help reduce our carbon footprint




renewable electricity by 2024 Continuously



Multi-fuel & green backed

combustion processes



Fulfilling our goals

Any minority, remaining balance will be from validated, ethical sources

Ethical Carbon offsetting

W ZERC

Total emissions

•••• Scope 1 emissions


Scope 2 emissions



TRAJECTORY OF EMISSIONS WITHOUT INTERVENTION

END-MARKET OUTLOOK

H2 2022*





SUMMARY & OUTLOOK FOR H2 2022

- ANTICIPATED VOLUME IMPROVEMENT (vs H1)
- MITIGATION PLANS FOR ADDITIONAL INFLATION
- REMAIN FOCUSED ON YEAR-ON-YEAR GROWTH
- LONG TERM OPPORTUNITIES REMAIN STRONG
- STRONG & GROWING ESG CREDENTIALS






PIPELINE MILESTONES

PROGRAMME	REVENUE STATUS	H1 2022 MILESTONES	FY 2022 FOCUS
MAGMA	Meaningful (£1m-£2m)	 TechnipFMC acquisition for Brazil scale up Support for qualification programme 	6 inch qualification pipeSupport for Brazil capex/scale up
AERO BRACKETS	Meaningful (£1m-£2m)	Application pipeline progression	 Progress revenue beyond £2m Further develop eVTOL opportunities
GEARS	Meaningful (£1m-£2m)	Further revenue growthStrong portfolio of programmes	 Progress revenue beyond £2m Commercialise development agreements (existing & new)
DENTAL	< £1m	Revenue growth	 Leverage clinical data (5 year data) Continue to explore adoption via OEM partners
TRAUMA	< £1m	Preparations for In2Bones launchAsia opportunities progressed	 Multiple plate launches (US & Asia) First OEM deployment Manufacturing collaboration
AERO STRUCTURES	< £1m	 Prototype revenues progressing Expanded OEM collaborations 	 Support Clean Sky2 assembly prototypes Achieve meaningful revenue (prototype revenue)
KNEE	n/a	 15 implants, 3 post 12 month stage Closing in on additional development partner (top 5 orthopaedic company) 	 Further implants on clinical trial Build capability ahead of commercialisation
E-MOBILITY	< £1m	 New business wins Further increase in development programmes 	Wire coating OEM launchClose on meaningful revenues

GROUP END MARKETS

H1 2022: 2,264 tonnes

H1 2021: 2,087 tonnes




^{*} Medical volume reflects both non-implantable and implantable volumes

MEDICAL: KEY MARKETS


H1 2022: £27.8m

H1 2021: £24.9m

Revenue by Region (live FX)



Revenue by Market (live FX)



BUSINESS UNIT INCOME STATEMENTS

	H1 2022			H1 2021			
	Reported	Exc deals	Currency Spot Impact	Constant currency 1	As reported	Exc Deals	Constant currency 1
	£m	£m	£m	£m	£m	£m	£m
Industrial							
Revenue	132.3	132.3	3.6	135.9	126.0	126.0	8%
Loss on foreign currency net hedging	1.6	-	-	-	0.2	-	-
Gross profit *	61.0	59.3	4.0	63.2	59.5	59.3	6%
Gross margin %	46.1%			46.5%	47.2%		
Medical							
Revenue	27.8	27.8	0.1	27.9	24.9	24.9	12%
Loss on foreign currency net hedging	0.1	-	-	-	0.3	-	-
Gross profit *	24.1	24.1	0.1	24.2	21.9	21.6	12%
Gross margin %	86.6%			88.1%	85.8%		

BALANCE SHEET

	H 1 2022	H I ZUZ I
	£m	£m
PPE and intangible assets	345.0	307.3
Financial assets held at FVTPL* and Investment in Associates	19.8	21.9
Inventories	79.9	81.0
Cash**	45.8	79.6
Trade receivables and other assets	78.9	62.6
Retirement benefit asset	15.8	6.2
Borrowings***	(15.6)	(5.5)
Lease liabilities	(9.0)	(8.9)
Trade payables and other liabilities	(90.0)	(60.0)
Equity shareholders' funds	470.6	484.2

H1 2021


^{*} Financial assets held at fair value through profit and loss ("FVTPL")

^{**} Includes £3.8m of cash is ring-fenced in the China subsidiary

^{***} Borrowings comprises £9.4m bank borrowings in China related to the funding of the PVYX plant (H1 2021: nil) plus £6.2m (H1 2021: £5.5m) related to the loan from the PVYX non-controlling interest

INVENTORY

Rebuild of raw material inventory...



H1 2022 INVENTORY £80m REFLECTING RAW MATERIAL REBUILD

• Maintain short-term inventories c£70-£80m to reflect raw materials, supply chain uncertainties & customer service levels

STRONG SERVICE LEVELS FOR CUSTOMERS

• OTIF (On time in full) >90% in FY 2022 YTD

DEFINITIONS

ALTERNATIVE PERFORMANCE MEASURES:

- 1) Constant currency metrics are reached by applying current year (FY 2022) weighted average spot rates to prior year (FY 2021) transactions. Gains and losses on foreign currency net hedging, are shown separately in the Income Statement and are excluded from the constant currency calculation;
- 2) Underlying PBT is profit before exceptional items and tax;
- 3) Operating cash conversion is operating profit before exceptional items adjusted for depreciation and amortisation, working capital and capital expenditure / operating profit before exceptional items;
- 4) Available cash is cash and cash equivalents plus other financial assets (cash invested in term deposits greater than three months in duration) less cash ring-fenced in the Group's Chinese subsidiaries which is committed to capital investment or additional capability and therefore not available to the wider group;
- 5) Total overheads is operating overheads made up of sales, marketing and administrative expenses before exceptional items;
- 6) Underlying EPS is earnings per share based on profit after tax but before exceptional items divided by the weighted average number of shares in issue; and
- 7) Mature Annualised Revenue is a measure of new application targets within our core business (excluding mega-programmes) and would be realised only if all targets convert to commercial revenues.

First to commercialise PEEK, with unmatched knowledge and experience



INFORMATION & CONTACTS

Andrew Hanson

Director of IR & **Corporate Communications**

> +44 (0) 1253 898121 +44 (0) 7809 595831 ir@victrex.com www.victrexplc.com

TO CREATE NEW MARKETS







ENERGY & INDUSTRIAL



UNDERPIN: SAFETY, SUSTAINABILITY

- Health & safety
- Sustainable business with sustainable products



POLYMER MANUFACTURING

Delivering the key PEEK & PAEK materials with No.1 manufacturing capacity of 7,150 tonnes



POLYMER

Producing new grades including for Additive Manufacturing (3D Printing)



PRODUCT FORMS Manufacturing product forms: Pipes,

Films, Fibres and Composite Tapes

PARTS & COMPONENTS

Developing new applications for PEEK, PAEK and Thermoplastic Composites



INVESTMENT IN INNOVATION

GLOBAL CAPABILITY

800+

Employees

Countries served by Victrex across

40+

our markets

c£2bn

Market Value

- FTSE 250 Company
- c£300m Revenue

c5-6% c£150m

of annual sales invested in R&D

Invested in manufacturing facilities in the last 5 years

Partnerships

NEW

- Strategic Alliances
- Polymer Innovation Centre

CAPABILITIES

- Acquisitions
- Composites Manufacturing
- Additive Manufacturing

